Utilization of Patient-Controlled Analgesia Reduces Length of Stay of Sickle Cell Crisis Hospitalizations

Prestia, Brett M; Ramzan, Talha; Waldron, C B; Malik, Ameer; Pallay, Robert; Murbach, Candace R; Flynn, Mike G.; Shaw, Eric; Kutlar, Abdullah; Lowe, Daniel

doi:10.36518/2689-0216.1275

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to Ballas & Dampier, roughly 60% of individuals with SCD visit the hospital for VOC treatment at least once a year and close to 25% require hospital-based VOC treatment five or more times annually ( 6 ). Of note, Prestia and colleagues reported healthcare visits for active vaso-occlusive crisis account for 95% of hospitalizations with an average length of stay of 4.5 days ( 37 ).…”

Section: Discussionmentioning

confidence: 99%

Single nucleotide polymorphisms and sickle cell disease-related pain: a systematic review

Gehling,

Powell-Roach,

Wilkie

et al. 2023

Front. Pain Res.

View full text Add to dashboard Cite

BackgroundScientists have speculated genetic variants may contribute to an individual's unique pain experience. Although research exists regarding the relationship between single nucleotide polymorphisms and sickle cell disease-related pain, this literature has not been synthesized to help inform future precision health research for sickle cell disease-related pain. Our primary aim of this systematic review was to synthesize the current state of scientific literature regarding single nucleotide polymorphisms and their association with sickle cell disease-related pain.MethodsUsing the Prisma guidelines, we conducted our search between December 2021–April 2022. We searched PubMed, Web of Science, CINAHL, and Embase databases (1998–2022) and selected all peer-reviewed articles that included reports of associations between single nucleotide polymorphisms and sickle cell disease-related pain outcomes.ResultsOur search yielded 215 articles, 80 of which were duplicates, and after two reviewers (GG, JD) independently screened the 135 non-duplicate articles, we retained 22 articles that met the study criteria. The synthesis of internationally generated evidence revealed that this scientific area remains predominantly exploratory in nature, with only three studies reporting sufficient power for genetic association. Sampling varied across studies with a range of children to older adults with SCD. All of the included articles (n = 22) examined acute pain, while only nine of those studies also examined chronic pain.ConclusionCurrently, the evidence implicating genetic variation contributing to acute and chronic sickle cell disease-related pain is characterized by modestly powered candidate-gene studies using rigorous SCD-pain outcomes. Effect sizes and directions vary across studies and are valuable for informing the design of future studies. Further research is needed to replicate these associations and extend findings with hypothesis-driven research to inform precision health research.

show abstract

Section: Discussionmentioning

confidence: 99%